TVCMALL
12.3.2023 08:16:39 CET | Business Wire | Pressemeddelelse
Nylig blev Mobile World Congress (MWC) 2023 afholdt i Barcelona, og det var en stor succes. Mere end 88 000 deltagere og 2400+ udstillere deltog i denne begivenhed, herunder mange leverandører af mobiltelefontilbehør og grossister. Som Europas førende one-stop-shop for mobiltilbehør og engros/integreret forsyningskædeserviceplatform, TVCMALL deltaget også i dette digitale/mobile arrangement. TVCMALL, der er baseret i Shenzhen, Kina, som er verdens elektroniske center, tilbyder kunder en B2B mobiltilbehør engros-, sourcing- og tilpasningsløsning. Forskellige klassiske mobiltelefoncovers med læderfinish, opladere med multifunktioner og Amorus bærbare karaokehøjtalere fra TVCMALL fik stor ros af de fremmødte.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20230307005694/da/
TVCMALL brings one-stop wholesale solution to MWC 2023 (Photo: Business Wire)
MWC er en af verdens vigtigste telekommunikations- og teknologimesser. I løbet af de sidste 4 dage er aspekter som den seneste trend inden for mobilteknologi inklusive intelligent udstyr, 5G-netværk, AI og digitalisering blevet introduceret og delt med resten af verden.
Under showet mødte TVCMALL mange gamle kunder og mange nye venner. Mange af dem er som følger:
- Top forhandlere og distributører af mobiltelefontilbehør online
- B2C platform sælgere, Dropshippere
- Fysiske butikker, supermarkedssælgere, teleselskaber
- Gave-Tilpasningskunder (især for myndigheder, virksomheder, skoler og andre offentlige ydelser)
- OEM & ODM & OBM kunder
- Detail & Mobiltelefon værksteder
Mange kunder har samarbejdet med TVCMALL i over ti år siden etableringen i 2008, og de er vokset og udviklet sig hurtigt med TVCMALL. De udtrykte deres store påskønnelse og store taknemmelighed til TVCMALL for at levere en one-stop shop til engros, sourcing, tilpassede tjenester og andre forsyningskædetjenester.
Hvorfor de vælger TVCMALL som énuundgåelig og vigtig langsigtet partner? Fordi TVCMALL tilbyder et komplet produktkatalog med mere end 600.000 SKU'er online, og hver uge opdateres 6.000 nye produkter. Engros-processen, marketingsupport og kundeservice er effektive. TVCMALL har gode intentioner om at vokse sammen med sine kunder.
TVCMALLs omfattende anskaffelsesomkostninger er relativt lave, servicekonsistens og stabilitet er meget stærk. Derfor foretrækker mange kunder one-stop-tjenesteudbydere som TVCMALL.
Under MWC har TVCMALL etableretgod kontakt med nogle fremragende produktleverandører og e-handelstjenesteudbydere (af mobile, 3C elektroniske enheder og tilbehør).
Ii den nærmeste fremtid, med kontinuerlig TVCMALL brand og platform opgradering, vil TVCMALL styrke sit mål, "At hjælpe iværksættere med at realisere deres drømme om at lancere og opretholde en succesfuld detailforretning", og vil overholde sin forretningsdriftsfilosofi "Together we thrive". Med hensyn til specifikke strategier vil TVCMALL følge de 4 følgende anvisninger:
- Platform branding —Betjen TVCMALL-platformen som et fremtidigt århundrede gammelt brand
- Produktisering af tjenesterne - alle tjenester fra TVCMALL sammen med ideen om produktisering.
- ProduktDyb pløjning — For at være den bedste skal du trives.
- Lokalisering af TVCMALL-tjenesten — Gå globalt og lokalisere: Start lokalt marketing- og serviceteam, dybdegående forståelse og effektiv service.
TVCMALL vil se dig igen i Barcelona 2024!
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20230307005694/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum